3:53 PM
 | 
Apr 05, 2019
 |  BC Extra  |  Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

Editor's Note: This article was updated on Apr 08, 2019 at 12:38 PM PDT

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg, the GI and metabolic disease company’s EVP and chief medical and development officer, who took on the CEO role on an interim basis after Britt Meelby Jensen’s departure in February.

The Institute for Clinical and Economic Review hired Pamela...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >